Abstract

Spinally administered muscarinic receptor agonists or acetylcholinesterase inhibitors produce effective pain relief. Intrathecal injection of a small dose of neostigmine produces a profound antiallodynic effect in rats with diabetic neuropathy. However, the mechanisms of increased antinociceptive effect of cholinergic agents on diabetic neuropathic pain are not clear. In the present study, we tested the hypothesis that spinal muscarinic receptors are up-regulated in diabetes. The withdrawal threshold of the hindpaw in response to noxious heat and pressure stimuli was determined in streptozotocin-induced diabetic and age-matched normal rats. Muscarine-stimulated guanosine 5′-O-(3-[³⁵S]thio)triphosphate ([³⁵S]GTPγS) binding was used to assess the change of functional muscarinic receptors in the spinal cord in diabetes. The [³H]AF-DX 384 membrane binding was performed to determine the number and affinity of spinal cord M2 muscarinic receptors in normal and diabetic rats. We found that the antinociceptive effect of intrathecal 2 to 12 μg muscarine in diabetic animals was potentiated significantly compared with that in normal animals. The maximal muscarine-stimulated [³⁵S]GTPγS binding was 112.5 ± 8.3% in normal rats and 168.8 ± 12.1% (P < 0.05) in diabetic rats. Although the K_D value (2.9 nM) was similar in both groups, the B_max of [³H]AF-DX 384 membrane binding was significantly higher in diabetic than in normal rats (255.2 ± 5.9 versus 165.9 ± 3.5 fmol/mg protein, P < 0.05). Collectively, these data strongly suggest that the muscarinic receptor is up-regulated in the dorsal spinal cord in diabetic rats. This finding probably accounts for the increased efficacy of the antinociceptive effect of intrathecal muscarinic agonists in diabetic neuropathic pain.